DCC-3084

N/A

Report date: 2026/03/04 20:01:44
NME

Base Information

Drug NameDCC-3084
Drug Alias NameDCC-3084
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRAF serine/threonine protein kinase inhibitors
TargetsRAF serine/threonine protein kinase
Therapy Area/IndicationsSolid tumoursProstatic Neoplasms, Castration-ResistantCarcinoma, Non-Small-Cell Lung +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesDeciphera Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesDeciphera Pharmaceuticals Inc
Inactive CompaniesDeciphera Pharmaceuticals Llc
Active IndicationsSolid tumoursHematologic Neoplasms
Inactive IndicationsProstatic Neoplasms, Castration-ResistantCarcinoma, Non-Small-Cell LungCarcinoma, Pancreatic Ductal +[4] 

Other Information

ATC CodeN/A
Related LinksN/A